Close mobile menu×
Close mobile menu

Nicole Lamanna, MD

Board Certifications: 
Medical Oncology
Expertise in: 
Leukemia, Cancer Care
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098
New Patients: 
(212) 305-5098
Existing Patients: 
(646) 317-5077

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Medical Oncology

Clinical Expertise

  • Leukemia
  • Cancer Care
  • Acute Leukemia
  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Acute Myeloid Leukemia
  • Chronic Leukemia
  • Chronic Lymphoid Leukemia
  • Chronic Myelogenous Leukemia
  • Essential Thrombocythemia
  • Hairy Cell Leukemia
  • Hematologic Malignancy
  • Hemolytic Anemia
  • Waldenstrom's Macroglobulinemia
  • Polycythemia Vera
  • Myeloproliferative Disorder
  • Myelofibrosis
  • Myelodysplastic Syndrome
  • Large Granular Lymphocytic Leukemia
  • Immune Thombocytopenic Purpura
  • Chronic Lymphocytic Leukemia

Specialties

Education & Training

  • MD, Albert Einstein College Medicine
  • 1998 Albert Einstein College of Medicine
  • Residency: New York University Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center

About Nicole Lamanna

biography_-_dr._nicole_lamanna

Nicole Lamanna, MD, is an Associate Clinical Professor of Medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division. Dr. Lamanna is a hematologist/oncologist whose research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia.

She is an experienced clinical investigator and her research focus has been the development of combination therapies that include chemoimmunotherapy, immunomodulatory drugs, novel kinase inhibitors and monoclonal antibodies. She also is working to find active, safer therapies for older patients with these diseases.

She earned her medical degree from Albert Einstein College of Medicine and completed her fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.

Academic Titles

  • Associate Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
Garden Level
New York, New York 10032
Phone:
(212) 305-5098
Fax:
(212) 305-8112
Primary

Research

Grants

A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF ACALABRUTINIB (ACP-196) IN COMBINATION WITH VENETOCLAX WITH AND WITHOUT OBINUTUZUMAB COMPARED TO INVESTIGATOR?S CHOICE OF CHEMOIMMUNOTHERAPY IN SUBJECTS WITH PREVI (P&S Industry Clinical Trial)

Dec 11 2019 - Dec 11 2024

RETROSPECTIVE CHART REVIEW OF SAFETY AND FEASIBILITY OF ACCELERATED RAMP-UP FOR VENETOCLAX IN REFECTORY/RELAPSED (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) PATIENTS PROGRESSED ON B CELL RECEPTOR INHIBITORS (BCRI) (P&S Industry Clinical Trial)

Oct 11 2019 - Oct 11 2024

A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN?S LYMPHOMA (NHL) (P&S Industry Clinical Trial)

Aug 20 2019 - Aug 20 2024

A PHASE 3, RANDOMIZED STUDY OF ZANUBRUTINIB (BGB-3111) COMPARED WITH IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (P&S Industry Clinical Trial)

Aug 14 2019 - Aug 14 2024

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) COLLABORATIVE STUDY OF REAL-WORLD EVIDENCE (CORE) (P&S Industry Clinical Trial)

Aug 13 2019 - Aug 13 2024

A PHASE I DOSE-ESCALATION STUDY OF THE SELECTIVE PKC- INHIBITOR MS- 553 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. (P&S Industry Clinical Trial)

Dec 5 2018 - Dec 5 2023

A SINGLE-ARM, SINGLE CENTER PHASE II TRIAL OF BENDAMUSTINE/RITUXIMAB INDUCTION FOLLOWED BY VENETOCLAX AND RITUXIMAB CONSOLIDATION FOR THE FRONTLINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (P&S Industry Clinical Trial)

Sep 24 2018 - Sep 24 2023

AN OPEN-LABEL, PHASE 1 SAFETY AND PHASE 2 RANDOMIZED STUDY OF JCAR017 IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (017004) (P&S Industry Clinical Trial)

Sep 11 2018 - Sep 11 2023

A PHASE 2 STUDY OF DUVELISIB EFFICACY AND SAFETY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL) PREVIOUSLY TREATED WITH A BRUTON?S TYROSINE KINASE INHIBITOR (BTKI)?. STUDY DRUG NEW DRUG, DUVELISIB IPI-145 (P&S Industry Clinical Trial)

Aug 22 2018 - Aug 22 2023

AN INTERNATIONAL, PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF BGB-3111 COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (P&S Industry Clinical Trial)

Apr 19 2018 - Apr 19 2023

A PHASE 1B-2 STUDY OF THE ROR1-TARGETING MONOCLONAL ANTIBODY, CIRMTUZUMAB (UC-961), AND THE BRUTON TYROSINE KINASE INHIBITOR, IBRUTINIB, IN PATIENTS WITH B-CELL LYMPHOID MALIGNANCIES (P&S Industry Clinical Trial)

Mar 27 2018 - Mar 27 2023

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GS-1101 (CAL-101) IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR PREVIOUSLY TREATED CHRNIC LYMPHOCYTIC LEUKEMIA (P&S Industry Clinical Trial)

Jun 17 2013 - Dec 31 2019

A PHASE 2 OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF ABT-199 (GDC-0199) IN CHRONIC LYMPHOCYTIC LEUKEMIA SUBJECTS WITH RELAPSE OR REFRACTORY TO B-CELL RECEPTOR SIGNALING PATHWAY INHIBITOR THERAPY (P&S Industry Clinical Trial)

Nov 20 2014 - Nov 20 2019

A STUDY OF IPI-145 AND OFATUMUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA PREVIOUSLY ENROLLED IN STUDY IPI-145-07 (P&S Industry Clinical Trial)

Aug 4 2014 - Aug 4 2019

A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB (P&S Industry Clinical Trial)

Aug 1 2014 - Aug 1 2019

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (P&S Industry Clinical Trial)

Jul 15 2014 - Jul 15 2019

PHASE 3 STUDY OF IPI-145 VERSUS OFATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (P&S Industry Clinical Trial)

Jun 24 2014 - Jun 24 2019